VGX-1027 is primarily investigated for its immunomodulatory properties, particularly in the context of autoimmune and inflammatory diseases. It has shown potential in preclinical studies for treating conditions such as type 1 diabetes by modulating the immune response and reducing inflammation in pancreatic islets. The compound acts by influencing cytokine production and immune cell activity, helping to prevent the destruction of insulin-producing beta cells. It is also being explored for use in other autoimmune disorders, including inflammatory bowel disease and rheumatoid arthritis, due to its ability to suppress pathogenic immune responses without causing broad immunosuppression. Research is ongoing to evaluate its efficacy and safety in clinical settings.